Oxaliplatin, 5-fluorouracil and leucovorin (modified FOLFOX-6) as first-line chemotherapy for advanced gastric cancer patients with poor performance status

Oncology Letters

Volumn 3, Issue 2, 2012, Pages 425-428

  Kim, Hyeong Su ^a   Kim, Jung Han ^a   Kim, Hee Jun ^a   Jang, Hyun Joo ^a   Kim, Jin Bae ^a   Kim, Ji Won ^a   Jung, So Young ^a   Kim, Byung Chun ^a   Yang, Dae Hyun ^a   Park, Soah ^b   Keong, Ju Kim ^b   Lee, Soon Il ^c   Zang, Dae Young ^a  

^a Hallym University College of Medicine   (South Korea)

^b Hallym University Medical Center   (South Korea)

^c Dankook University College of Medicine   (South Korea)

Author keywords

Advanced gastric cancer; Modified FOLFOX 6; Poor performance status

Indexed keywords

ANTIEMETIC AGENT; FLUOROURACIL; FOLINIC ACID; OXALIPLATIN;

ADULT; ADVANCED CANCER; AGED; ALLERGIC REACTION; ANEMIA; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CONTINUOUS INFUSION; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG FEVER; DRUG SAFETY; FEBRILE NEUTROPENIA; FEMALE; HAND FOOT SYNDROME; HUMAN; MALE; MEDICAL RECORD REVIEW; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; PERIPHERAL NEUROPATHY; REVIEW; SEPSIS; STOMACH CANCER; THROMBOCYTOPENIA; TREATMENT RESPONSE; VOMITING;

EID: 84855218274     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2011.496     Document Type: Review

References (14)

1. Jung KW, Park S, Kong, HJ, et al: Cancer statistics in Korea: incidence, mortality, survival, and prevalence in 2008. Cancer Res Treat 43: 1-11, 2011.
2. Greenlee RT, Murray T, Bolden S and Wingo PA: Cancer statistics. CA Cancer J Clin 50: 7-33, 2000.
3. Gunderson LL and Sosin H: Adenocarcinoma of the stomach: areas of failure in a reoperation series (second or symptomatic look) - clinicopathologic correlation and implications for adjuvant therapy. Int J Radiat Oncol Biol Phys 8: 1-11, 1982.
4. Catalano V, Labianca R, Beretta GD, et al: Gastric cancer. Crit Rev Oncol Hematol 54: 209-241, 2005.
5. de Gramont A, Figer A, Seymour M, et al: Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 18: 2938-2947, 2000.
6. Louvet C, Andre T, Tigaud JM, et al: Phase II study of oxaliplatin, fluorouracil, and folinic acid in locally advanced or metastatic gastric cancer patients. J Clin Oncol 20: 4543-4548, 2002.
7. Al-Batran SE, Atmaca A, Hegewisch-Becker S, et al: Phase II trial of biweekly infusional fluorouracil and folinic acid, and oxaliplatin in patients with advanced gastric cancer. J Clin Oncol 22: 658-663, 2004.
8. De Vita F, Orditura M, Matano E, et al: A phase II study of biweekly oxaliplatin infusional 5-fluorouracil and folinic acid (FOLFOX-4) as first-line treatment of advanced gastric cancer patients. Br J Cancer 92: 1644-1649, 2005.
9. Luo HY, Xu RH, Zhang L, et al: A pilot study of oxaliplatin, fluorouracil and folinic acid (FOLFOX-6) as first-line chemothetapy in advanced or recurrent gastric cancer. Chemotherapy 54: 228-235, 2008.
10. Liu ZF, Guo QS, Zhang XQ, et al: Biweekly oxaliplatin in combination with continuous infusional 5-fluorouracil and leucovorin (modified FOLFOX-4 regimen) as first-line chemotherapy for elderly patients with advanced gastric cancer. Am J Clin Oncol 31: 259-263, 2008.
11. Lee HH, Hur H, Kim SH, Park AR, Kim W and Jeon HM: Outcomes of modified FOLFOX-6 as first line treatment in patients with advanced gastric cancer in a single institution; retrospective analysis. Cancer Res Treat 42: 18-23, 2010.
12. Diaz-Rubio E: New chemotherapeutic advances in pancreatic, colorectal, and gastric cancers. Oncologist 9: 282-294, 2004.
13. Ibranhim A, Hirschfeld S, Cohen MH, et al: FDA drug approval summaries: oxaliplatin. Oncologist 9: 8-12, 2004.
14. Oh SY, Kwon HC, Lee S, et al: A phase II study of oxaliplatin with low-dose leucovorin and bolus and continuous 5-fluorouracil (modified FOLFOX-4) for gastric cancer patients with malignant ascites. Jpn J Clin Oncol 37: 930-935, 2007.